Adjuvant tamoxifen in primary breast cancer

Influence on plasma lipids and antithrombin III levels

G. Bertelli, P. Pronzato, D. Amoroso, M. P. Cusimano, P. F. Conte, G. Montagna, S. Bertolini, R. Rosso

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

The possible estrogenic effects of tamoxifen on plasma lipids and antithrombin III levels were investigated in 91 breast cancer patients. Mean values of total, HDL and LDL cholesterol, triglycerides, glucose, uric acid, and antithrombin III were evaluated in 55 patients on adjuvant tamoxifen for at least 3 months and compared with those found in 36 patients on no therapy. Total cholesterol, LDL cholesterol, and antithrombin III levels were significantly lower in treated patients (p

Original languageEnglish
Pages (from-to)307-310
Number of pages4
JournalBreast Cancer Research and Treatment
Volume12
Issue number3
DOIs
Publication statusPublished - Dec 1988

Fingerprint

Antithrombin III
Tamoxifen
Breast Neoplasms
LDL Cholesterol
Uric Acid
HDL Cholesterol
Estrogens
Cholesterol
Glucose
Lipid III
Therapeutics

Keywords

  • adjuvant endocrine therapy
  • antithrombin III
  • plasma lipids
  • tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adjuvant tamoxifen in primary breast cancer : Influence on plasma lipids and antithrombin III levels. / Bertelli, G.; Pronzato, P.; Amoroso, D.; Cusimano, M. P.; Conte, P. F.; Montagna, G.; Bertolini, S.; Rosso, R.

In: Breast Cancer Research and Treatment, Vol. 12, No. 3, 12.1988, p. 307-310.

Research output: Contribution to journalArticle

Bertelli, G. ; Pronzato, P. ; Amoroso, D. ; Cusimano, M. P. ; Conte, P. F. ; Montagna, G. ; Bertolini, S. ; Rosso, R. / Adjuvant tamoxifen in primary breast cancer : Influence on plasma lipids and antithrombin III levels. In: Breast Cancer Research and Treatment. 1988 ; Vol. 12, No. 3. pp. 307-310.
@article{23e311d99fa341c2b67255cfcdf6d035,
title = "Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels",
abstract = "The possible estrogenic effects of tamoxifen on plasma lipids and antithrombin III levels were investigated in 91 breast cancer patients. Mean values of total, HDL and LDL cholesterol, triglycerides, glucose, uric acid, and antithrombin III were evaluated in 55 patients on adjuvant tamoxifen for at least 3 months and compared with those found in 36 patients on no therapy. Total cholesterol, LDL cholesterol, and antithrombin III levels were significantly lower in treated patients (p",
keywords = "adjuvant endocrine therapy, antithrombin III, plasma lipids, tamoxifen",
author = "G. Bertelli and P. Pronzato and D. Amoroso and Cusimano, {M. P.} and Conte, {P. F.} and G. Montagna and S. Bertolini and R. Rosso",
year = "1988",
month = "12",
doi = "10.1007/BF01811244",
language = "English",
volume = "12",
pages = "307--310",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Adjuvant tamoxifen in primary breast cancer

T2 - Influence on plasma lipids and antithrombin III levels

AU - Bertelli, G.

AU - Pronzato, P.

AU - Amoroso, D.

AU - Cusimano, M. P.

AU - Conte, P. F.

AU - Montagna, G.

AU - Bertolini, S.

AU - Rosso, R.

PY - 1988/12

Y1 - 1988/12

N2 - The possible estrogenic effects of tamoxifen on plasma lipids and antithrombin III levels were investigated in 91 breast cancer patients. Mean values of total, HDL and LDL cholesterol, triglycerides, glucose, uric acid, and antithrombin III were evaluated in 55 patients on adjuvant tamoxifen for at least 3 months and compared with those found in 36 patients on no therapy. Total cholesterol, LDL cholesterol, and antithrombin III levels were significantly lower in treated patients (p

AB - The possible estrogenic effects of tamoxifen on plasma lipids and antithrombin III levels were investigated in 91 breast cancer patients. Mean values of total, HDL and LDL cholesterol, triglycerides, glucose, uric acid, and antithrombin III were evaluated in 55 patients on adjuvant tamoxifen for at least 3 months and compared with those found in 36 patients on no therapy. Total cholesterol, LDL cholesterol, and antithrombin III levels were significantly lower in treated patients (p

KW - adjuvant endocrine therapy

KW - antithrombin III

KW - plasma lipids

KW - tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0024272508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024272508&partnerID=8YFLogxK

U2 - 10.1007/BF01811244

DO - 10.1007/BF01811244

M3 - Article

VL - 12

SP - 307

EP - 310

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -